Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease

Ashwani K. Singal, Paul Kwo, Allison Kwong, Suthat Liangpunsakul, Alexandre Louvet, Pranoti Mandrekar, Craig McClain, Jessica Mellinger, Gyongyi Szabo, Norah Terrault, Mark Thursz, Gerald S. Winder, W. Ray Kim, Vijay H. Shah

Research output: Contribution to journalReview articlepeer-review


Alcohol-associated liver disease (ALD) is emerging worldwide as the leading cause of liver-related morbidity, mortality, and indication for liver transplantation. The ALD Special Interest Group and the Clinical Research Committee at the digital American Association for the Study of Liver Diseases meeting in November 2020 held the scientific sessions to identify clinical unmet needs in ALD, and addressing these needs using clinical research methodologies. Of several research methodologies, the sessions were focused on (a) studying disease burden of ALD using large administrative databases, (b) developing biomarkers for noninvasive diagnosis of alcohol-associated hepatitis (AH) and estimation of disease prognosis, (c) identifying therapeutic targets for ALD and AH, (d) deriving accurate models to predict prognosis or posttransplant alcohol relapse as a basis for developing treatment algorithm and a uniform protocol on patient-selection criteria for liver transplantation, and (e) examining qualitative research methodologies in studying the barriers to implementation of multidisciplinary integrated care model by hepatology and addiction teams for the management of dual pathology of liver disease and of alcohol use disorder. Prospective multicenter studies are required to address many of these clinical unmet needs. Further, multidisciplinary care models are needed to improve long-term outcomes in patients with ALD.

Original languageEnglish (US)
Pages (from-to)1026-1037
Number of pages12
Issue number4
StatePublished - Apr 2022

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease'. Together they form a unique fingerprint.

Cite this